uni-leipzig-open-access/json/s00066-023-02084-8

{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T04:21:09Z","timestamp":1685074869987},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Leipzig"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00066-023-02084-8","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T15:21:41Z","timestamp":1682004101000},"page":"604-606","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re-irradiation and Bevacizumab\u00a0\u2013 active combination for treatment of recurrent glioblastoma","Re-Bestrahlung und Bevacizumab\u00a0\u2013 wirksame Partner bei rezidiviertem Glioblastom"],"prefix":"10.1007","volume":"199","author":[{"given":"Clemens","family":"Seidel","sequence":"first","affiliation":[]},{"given":"Nils H.","family":"Nicolay","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"issue":"1","key":"2084_CR1","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijrobp.2008.10.043","volume":"75","author":"PH Gutin","year":"2009","unstructured":"Gutin\u00a0PH, Iwamoto\u00a0FM, Beal\u00a0K et\u00a0al (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75(1):156\u2013163. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.10.043","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2084_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11060-014-1394-5","volume":"117","author":"M Flieger","year":"2014","unstructured":"Flieger\u00a0M, Ganswindt\u00a0U, Schwarz\u00a0SB et al (2014) Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J\u00a0Neurooncol 117(2):337\u2013345. https:\/\/doi.org\/10.1007\/s11060-014-1394-5","journal-title":"J Neurooncol"},{"issue":"4","key":"2084_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3171\/2015.4.JNS15194","volume":"124","author":"LM Sagberg","year":"2016","unstructured":"Sagberg\u00a0LM, Solheim\u00a0O, Jakola\u00a0AS (2016) Quality of survival the 1st year with glioblastoma: a\u00a0longitudinal study of patient-reported quality of life. J\u00a0Neurosurg 124(4):989\u2013997. https:\/\/doi.org\/10.3171\/2015.4.JNS15194","journal-title":"J Neurosurg"},{"issue":"10","key":"2084_CR4","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.ejca.2015.03.025","volume":"51","author":"L Dirven","year":"2015","unstructured":"Dirven\u00a0L, van den Bent\u00a0MJ, Bottomley\u00a0A et al (2015) The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer 51(10):1321\u20131330. https:\/\/doi.org\/10.1016\/j.ejca.2015.03.025","journal-title":"Eur J Cancer"},{"issue":"4","key":"2084_CR5","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","volume":"13","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh\u00a0JJ, Desjardins\u00a0A, Herndon\u00a0JE et\u00a0al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253\u20131259. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2309","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2084_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl\u00a0TN, Kim\u00a0L, Moore\u00a0K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J\u00a0Clin Oncol 27(5):740\u2013745. https:\/\/doi.org\/10.1200\/JCO.2008.16.3055","journal-title":"J Clin Oncol"},{"issue":"19","key":"2084_CR7","first-page":"5565","volume":"60","author":"CG Lee","year":"2000","unstructured":"Lee\u00a0CG, Heijn\u00a0M, Di Tomaso\u00a0E et al (2000) Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60(19):5565\u20135570","journal-title":"Cancer Res"},{"issue":"5","key":"2084_CR8","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","volume":"79","author":"VA Levin","year":"2011","unstructured":"Levin\u00a0VA, Bidaut\u00a0L, Hou\u00a0P et al (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79(5):1487\u20131495. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.12.061","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2084_CR9","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.ijrobp.2019.06.539","volume":"105","author":"C Tsien","year":"2019","unstructured":"Tsien\u00a0C, Pugh\u00a0S, Dicker\u00a0AP et al (2019) Randomized phase II trial of re-irradiation and concurrent bevacizumab versus bevacizumab alone as treatment for recurrent glioblastoma (NRG oncology\/RTOG 1205): initial outcomes and RT plan quality report. Int J Radiat Oncol Biol Phys 105(1):S78. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.06.539","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2084_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1186\/s12885-016-2806-z","volume":"16","author":"O Oehlke","year":"2016","unstructured":"Oehlke\u00a0O, Mix\u00a0M, Graf\u00a0E et al (2016) Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA)\u2014protocol of a\u00a0randomized phase II trial (NOA 10\/ARO 2013-1). BMC Cancer 16(1):769. https:\/\/doi.org\/10.1186\/s12885-016-2806-z","journal-title":"BMC Cancer"},{"issue":"1","key":"2084_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11060-011-0722-2","volume":"107","author":"DA Reardon","year":"2012","unstructured":"Reardon\u00a0DA, Desjardins\u00a0A, Peters\u00a0KB et\u00a0al (2012) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab na\u00efve, recurrent glioblastoma. J\u00a0Neurooncol 107(1):155\u2013164. https:\/\/doi.org\/10.1007\/s11060-011-0722-2","journal-title":"J Neurooncol"},{"issue":"11","key":"2084_CR12","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/neuonc\/nov104","volume":"17","author":"KM Field","year":"2015","unstructured":"Field\u00a0KM, Simes\u00a0J, Nowak\u00a0AK et\u00a0al (2015) Randomized phase 2\u00a0study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol 17(11):1504\u20131513. https:\/\/doi.org\/10.1093\/neuonc\/nov104","journal-title":"Neuro Oncol"},{"issue":"20","key":"2084_CR13","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick\u00a0W, Gorlia\u00a0T, Bendszus\u00a0M et\u00a0al (2017) Lomustine and bevacizumab in progressive glioblastoma. N\u00a0Engl J Med 377(20):1954\u20131963. https:\/\/doi.org\/10.1056\/NEJMoa1707358","journal-title":"N Engl J Med"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02084-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-023-02084-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02084-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T18:03:36Z","timestamp":1685037816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-023-02084-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2084"],"URL":"http:\/\/dx.doi.org\/10.1007\/s00066-023-02084-8","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":["Oncology","Radiology, Nuclear Medicine and imaging"],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"5 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.\u00a0Seidel hat Honorare f\u00fcr Vortr\u00e4ge und Advisory Boards von\u00a0AbbVie, Bristol-Myers Squibb, HRA Pharma, medac, Novocure, Roche und Seagen und Forschungsf\u00f6rderung von Seagen and Amgen erhalten. N.H.\u00a0Nicolay hat Honorare f\u00fcr Vortr\u00e4ge von Merck und Novocure und Forschungsf\u00fcrderung von Novocure erhalten.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}